AXLA
Axcella Health Inc. [AXLA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AXLA Stock Summary
In the News
AXLA Financial details
Company Rating
-
Market Cap
1.18M
Income
-50.03M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-0.59
Forward P/E
-
PEG
0.12
P/S
-
P/B
-13.08
P/C
-
P/FCF
-0.03
Quick Ratio
0.77
Current Ratio
0.8
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.9
EPS next Y
-
EPS next Q
-
EPS this Y
-13.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.57%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-539%
ROE
4068%
ROC
20.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.34-41.25
52W High
-
52W Low
-
RSI
-
Rel Volume
0.12
Avg Volume
54.52K
Volume
6.78K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.575
-
-
Volatility
0%, 0%
Prev Close
0%
Price
4.58
Change
1172.22%
Company Profile
- Volume Average 54.52K
- Market Capitalization 1.18M
- Employee 11
- CEO Mr. Craig R. Jalbert CIRA
- Headquarters Cambridge,MA,US
- IPO Date 2019-05-09
-
Website
https://www.axcellahealth.com 
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
